Blackstone offers $1bn private credit to refinance Signant loans.

Blackstone has arranged a private credit package in excess of $1bn to replace traditional bank funding for Signant Health, marking another example of direct lenders stepping into the leveraged-finance space. The financing combines a unitranche term loan, a delayed-draw facility and a revolving credit line priced at 4.75 percentage points over SOFR.

Sources indicate Blackstone will keep a majority of the exposure, with other private lenders expected to join later. The move substitutes a bank-led structure that previously totalled more than $1bn in commitments and follows Signant’s December 2024 repricing, when it trimmed the spread on a $968m first‑lien loan to 4.25 points over SOFR.

The borrower still carries additional layers of debt, including roughly $230m in second‑lien term paper and an $80m revolver. By shifting the capital stack toward direct lending, Signant’s sponsors have traded the syndicated loan market for a privately negotiated structure that can offer greater covenant flexibility and execution speed.

This deal underscores a broader pattern: private-credit managers have been pruning banks out of refinancing mandates across sectors. JPMorgan Chase data show roughly $37.1bn of syndicated loans have moved into private credit this year, compared with about $34.7bn flowing the other way — a dynamic that highlights active arbitrage between public and private lenders.

The transaction also speaks to the appeal of unitranche executions for mid‑market and sponsor-backed borrowers. For lenders, these structures pack higher yields and hold fewer syndication risks; for private equity owners, they reduce refinancing uncertainty. Industry estimates place global private credit assets well above the billion‑dollar mark, supporting larger, more complex financings than a decade ago.

Signant — acquired by its sponsor in 2018 and integrated with Bracket to create a digital clinical-trials technology platform — operates in a sector where subscription‑style revenues and sticky client relationships are attractive to direct lenders seeking resilient cashflows. For private-credit houses, life‑sciences services provide portfolio diversification away from cyclical industrial exposures.